Salidroside
description1
description2
Basic information
Product Name: Salidroside
IUPAC Name: 2-(4-Hydroxyphenyl)ethyl-β-D-glucopyranoside
CAS No.: 10338-51-9
Molecular Formula: C₁₄H₂₀O₇
Physicochemical Properties:
Parameter |
Value/Description |
Appearance |
White powder |
Melting Point |
159–161°C |
Solubility |
50 mg/mL in water; soluble in methanol/ethanol |
logP |
-0.7 (high hydrophilicity) |
Optical Rotation |
[α]²⁵D = -42° (c=1, water) |
Stability |
Stable at pH 3–7; light-sensitive |
Quality Standard: CP2020,JP,Customer Made
Specification
Test Items |
Standard |
Salidroside (CAS: 10338-51-9) |
98% by HPLC |
Loss on drying |
≤3.0% |
Residue on ignition |
≤1.0% |
Natural Source
Multi-Target Action
Rapid Absorption
1.Molecular Target Network
2. Pharmacokinetics
Absorption
68% oral bioavailability (glucose transporter-mediated).
Distribution
Brain/plasma ratio = 1.5:1 (BBB-penetrant).
Metabolism
Gut microbiota hydrolyzes to tyrosol (active metabolite).
Excretion
80% urinary excretion (t½ = 2.5 h).
Clinical Applications
Indications & Protocols
Condition |
Regimen |
Evidence |
Chronic Fatigue Syndrome |
200 mg/day ×4 weeks |
↓40% fatigue score* |
Mild Cognitive Impairment |
100 mg bid ×6 months |
↑3 MMSE points |
Altitude Sickness Prevention |
300 mg/day (3 days pre-ascent) |
↑8% SpO₂ |
*Randomized double-blind trial (n=150)
Special Populations
Hepatic Impairment: Reduce dose 30% (Child-Pugh B).
Pediatrics: 12–18 years (5 mg/kg/day).
Dosage and Administration
Formulations
Tablets: 50 mg/tablet (microcrystalline cellulose).
Oral Solution: 10 mg/mL (flavored).
Injection: 20 mg/2 mL (research use).
Dosing Guidelines
Use |
Dose |
Duration |
Anti-Fatigue |
100–200 mg/day |
2–4 weeks |
Neuroprotection |
50–100 mg bid |
3–6 months |
Acute Hypoxia |
300 mg loading dose |
Short-term |
Safety Evaluation
Adverse Reactions
System |
Incidence |
Manifestations |
Gastrointestinal |
3% |
Mild nausea |
Neurological |
1% |
Transient dizziness |
Hypersensitivity |
0.1% |
Rash |
Contraindications & Interactions
Absolute CI:
Phenylethanoid allergy.
Severe hypotension (SBP <85 mmHg).
Cautions:Antidepressants (synergistic 5-HT activation).
Research Progress Green max
Novel Formulations
Nano-Crystalline Self-Stabilizing System: ↑Bioavailability to 85%.
Sublingual Fast-Dissolving Tablets: 5-min onset (for acute altitude sickness).
New Indications
Post-COVID Fatigue: Phase II trials ongoing.
Parkinson’s Disease: Protects dopaminergic neurons (↑30% TH+ cells in animals).
Please Send me email and you can get more what you want.
Such as product of Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.
Our experts will solve them in no time.